High Response Rates and Predictors in Patients with CRSwNP Treated With Mepolizumab and Dupilumab: Results From a Prospective, Multicenter Cohort Study - PubMed
5 hours ago
- #CRSwNP
- #real-world study
- #biologics
- Dupilumab and mepolizumab are effective add-on therapies for severe CRSwNP (chronic rhinosinusitis with nasal polyps).
- Study aimed to identify baseline predictors of response and compare outcomes between dupilumab and mepolizumab at 6 and 12 months.
- Both biologics significantly improved SNOT-22, total symptom score (TSS), and nasal polyp score (NPS) at both time points with comparable efficacy.
- Dupilumab showed superior improvement in olfaction compared to mepolizumab.
- High response rates: 84.2% achieved good/excellent response at 6 months and 89.6% at 12 months.
- Factors associated with better response included comorbid asthma and a shorter time since the last surgery.
- Asthma and surgical history may help predict response to these biologics.